ß-thalassemia Clinical Trial
Official title:
An Open Label Extension Study of PTG-300 In Non-Transfusion Depenent (NTD) and Trasfusion-Dependent (TD) B-Thalassemia Subjects
In this study will investigate long term safety and use of the PTG-300 in Beta Thalassemia patients.
The PTG-300-03 study will study beta thalassemia patients on PTG-300 for two years. The dose and dose frequency for each subject enrolling in the PTG-300-03 study will be based on the last dose and frequency received by the subject in the previous study PTG-300-02 and the subject's response at that dose. Patients dose will be increased in a manner similar to that used on PTG-300-02 study. The maximum PTG-300 dose allowed is 80 mg/week. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00560820 -
Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload
|
Phase 1 | |
| Recruiting |
NCT05773729 -
Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent Beta-thalassemia
|
N/A | |
| Recruiting |
NCT05864170 -
the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia
|
Early Phase 1 | |
| Not yet recruiting |
NCT06440603 -
EKLF Gene Expression in β-thalassemia
|
||
| Completed |
NCT03802201 -
Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia
|
Phase 2 | |
| Recruiting |
NCT05745532 -
Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients
|
Early Phase 1 | |
| Not yet recruiting |
NCT03358498 -
Quality of Life and Treatment Satisfaction in β-Thalassemia Patients Receiving Deferasirox
|
N/A | |
| Recruiting |
NCT05494333 -
Correlation Between Pulmonary Functions and Physical Fitness in Children With β-thalassemia
|